1. Zhao, Yan, Zhu Wei, Yanyan Feng, et al. “Efficacy and Safety of
Benvitimod 1% Cream for Atopic Dermatitis in Patients Aged 2 Years
and Older: A Phase III Randomized Clinical Trial.” Chinese Medical
Journal, ahead of print, September 16, 2025.
https://doi.org/10.1097/CM9.0000000000003769.
2. Gold, Linda Stein, James Del Rosso, Benjamin D. Ehst, et al.
“Tapinarof Cream 1% Once Daily Was Well Tolerated in Adults and
Children with Atopic Dermatitis in Two Phase 3 Randomized Trials.”
Journal of Dermatological Treatment 36, no. 1 (2025): 2444489.
https://doi.org/10.1080/09546634.2024.2444489.
3. Silverberg, Jonathan I., Lawrence F. Eichenfield, Adelaide A.
Hebert, et al. “Tapinarof Cream 1% Once Daily: Significant Efficacy
in the Treatment of Moderate to Severe Atopic Dermatitis in Adults
and Children down to 2 Years of Age in the Pivotal Phase 3 ADORING
Trials.” Journal of the American Academy of Dermatology 91, no. 3
(2024): 457–65. https://doi.org/10.1016/j.jaad.2024.05.023.
4. Fardos, Mohammad, Nithisha Cheedalla, Austin Raj Watson, and
David Esguerra. “Tapinarof in Atopic Dermatitis: A Comprehensive
Scoping Review of Clinical Efficacy and Safety.” JAAD Reviews 3
(March 2025): 69–77. https://doi.org/10.1016/j.jdrv.2024.12.001.
5. Zhao, Yan, Chenyu Wu, Lin Cai, et al. “Tapinarof Inhibits
Psoriatic Inflammation through Inducing Tolerogenic Dendritic Cells
and Foxp3+ Tregs.” Chinese Medical Journal 137, no. 23 (2024):
2877–79. https://doi.org/10.1097/CM9.0000000000003260.
6. Quintana, Francisco J., Alexandre S. Basso, Antonio H. Iglesias,
et al. “Control of Treg and TH17 Cell Differentiation by the Aryl
Hydrocarbon Receptor.” Nature 453, no. 7191 (2008): 65–71.
https://doi.org/10.1038/nature06880
7. Igarashi, Atsuyuki, Gaku Tsuji, Shuichi Fukasawa, Ryusei Murata,
and Satoshi Yamane. “Tapinarof Cream for the Treatment of Atopic
Dermatitis: Efficacy and Safety Results from Two Japanese Phase 3
Trials.” The Journal of Dermatology 51, no. 11 (2024): 1404–13.
https://doi.org/10.1111/1346-8138.17451.
8. Smith, Susan H., Channa Jayawickreme, David J. Rickard, et al.
“Tapinarof Is a Natural AhR Agonist That Resolves Skin Inflammation
in Mice and Humans.” Journal of Investigative Dermatology 137, no.
10 (2017): 2110–19. https://doi.org/10.1016/j.jid.2017.05.004.
9. Di Meglio, Paola, João H. Duarte, Helena Ahlfors, et al.
“Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of
Inflammatory Skin Conditions.” Immunity 40, no. 6 (2014): 989–1001.
https://doi.org/10.1016/j.immuni.2014.04.019.
10. Van Den Bogaard, Ellen H., Judith G. M. Bergboer, Mieke
Vonk-Bergers, et al. “Coal Tar Induces AHR-Dependent Skin Barrier
Repair in Atopic Dermatitis.” Journal of Clinical Investigation,
January 25, 2013, JCI65642. https://doi.org/10.1172/JCI65642.
11. Chen, Zeyu, Morgan Dragan, Peng Sun, et al. “The AhR-Ovol1-Id1
Regulatory Axis in Keratinocytes Promotes Epidermal and Immune
Homeostasis in Atopic Dermatitis-like Skin Inflammation.” Cellular &
Molecular Immunology 22, no. 3 (2025): 300–315.
https://doi.org/10.1038/s41423-025-01264-z.
12. Jia, Qiuyu, Ping Liu, Xiaojie Wang, et al. “Benvitimod
Upregulates Filaggrin, Involucrin and Loricrin Expressions via Aryl
Hydrocarbon Receptor-OVO-like 1 Axis.” Archives of Dermatological
Research 316, no. 8 (2024): 585.
https://doi.org/10.1007/s00403-024-03268-7.
13. Tsuji, Gaku, Akiko Hashimoto-Hachiya, Mari Kiyomatsu-Oda, et al.
“Aryl Hydrocarbon Receptor Activation Restores Filaggrin Expression
via OVOL1 in Atopic Dermatitis.” Cell Death & Disease 8, no. 7
(2017): e2931–e2931. https://doi.org/10.1038/cddis.2017.322.
14. Wang, Xiaojie, Dandan Mao, Jun Jia, and Jianzhong Zhang.
“Benvitimod Inhibits IL-4– and IL-13–Induced Tight Junction
Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6
Phosphorylation in Human Keratinocytes.” Journal of Investigative
Dermatology 144, no. 3 (2024): 509-519.e7.
https://doi.org/10.1016/j.jid.2023.07.027.
15. Polonio, Carolina M., Kimberly A. McHale, David H. Sherr, David
Rubenstein, and Francisco J. Quintana. “The Aryl Hydrocarbon
Receptor: A Rehabilitated Target for Therapeutic Immune Modulation.”
Nature Reviews Drug Discovery, ahead of print, April 17, 2025.
https://doi.org/10.1038/s41573-025-01172-x.
16. Silverberg, Jonathan I., Mark Boguniewicz, Francisco J.
Quintana, et al. “Tapinarof Validates the Aryl Hydrocarbon Receptor
as a Therapeutic Target: A Clinical Review.” Journal of Allergy and
Clinical Immunology 154, no. 1 (2024): 1–10.
https://doi.org/10.1016/j.jaci.2023.12.013.
17. Diao, Xiaotong, Qinghong Shang, Mengqi Guo, et al. “Structural
Basis for the Ligand-Dependent Activation of Heterodimeric AHR-ARNT
Complex.” Nature Communications 16, no. 1 (2025): 1282.
https://doi.org/10.1038/s41467-025-56574-7.